Form 4: ImmuCell Director Exercises Options, Adjusts Holdings

ImmuCell Director Michael F. Brigham exercised stock options and adjusted common stock holdings, resulting in a net change in beneficial ownership.

Summary

• Director Michael F. Brigham exercised stock options to acquire 25,000 shares of ImmuCell Corporation common stock at an exercise price of $5.84 per share on March 20, 2026.
• The exercise was conducted through a stock-for-stock transaction, where previously owned shares were surrendered in full payment of the exercise price for the option.
• Concurrently, 24,052 shares were disposed of at a price of $6.07 per share to the Issuer, specifically for the payment of the option's exercise price.
• Following these transactions, Michael F. Brigham's direct beneficial ownership of common stock stands at 205,700 shares.
• The stock options, which had an exercise price of $5.84, were exercisable from February 10, 2017, and were set to expire on February 10, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While shares were disposed of, it was for a routine option exercise payment, and the director still holds a significant number of shares, indicating continued alignment with shareholder interests.

Positives

• Director Michael F. Brigham exercised stock options, indicating a realization of value from previously granted equity compensation.
• The exercise price of the options ($5.84) was below the price at which shares were disposed of for tax/exercise payment ($6.07), suggesting the options were in-the-money.

Negatives

• A portion of the acquired shares (24,052 shares) was immediately disposed of to cover the exercise price, which, while a common practice, reduces the net increase in the director's direct holdings from the option exercise.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises and subsequent share adjustments, are common occurrences in publicly traded companies. These transactions provide insights into management's personal financial activities related to their company's stock, though they are often pre-scheduled under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: Provides transparency into the director's equity holdings and compensation activities, potentially signaling continued insider confidence.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent share disposition to cover the exercise price. While it shows a director's engagement with their equity compensation, it does not present new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The net effect on beneficial ownership is a slight reduction from the peak after exercise but still represents a substantial holding, suggesting continued alignment without a strong signal for 'buy' or 'sell' based solely on this filing.

Keywords

ImmuCell Corporation, ICCC, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Director Transaction, Equity Compensation, Michael F. Brigham